Shield Therapeutics plc, of London, said it completed enrollment of the pivotal phase III AEGIS-CKD study of European-marketed drug Feraccru (ferric maltol), with top-line data, based on the 16-week primary endpoint, anticipated early in the first quarter of 2018.